Key terms
About LUNG
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LUNG news
Apr 03
7:06am ET
Piper Sandler Remains a Buy on Pulmonx (LUNG)
Apr 02
4:23pm ET
Pulmonx Welcomes Mehul Joshi as New CFO with Comprehensive Compensation Package
Apr 02
4:14pm ET
Pulmonx appoints Mehul Joshi CFO
Feb 22
4:33pm ET
Wells Fargo downgrades Pulmonx on management uncertainty
Feb 22
4:22pm ET
Pulmonx downgraded to Equal Weight from Overweight at Wells Fargo
Feb 22
8:44am ET
Pulmonx price target raised to $20 from $18 at Craig-Hallum
Feb 22
7:49am ET
Pulmonx price target raised to $16 from $15 at Canaccord
Feb 22
7:44am ET
Pulmonx price target raised to $17 from $15 at Stifel
Feb 22
7:40am ET
Pulmonx price target raised to $17 from $13 at Piper Sandler
Feb 22
6:48am ET
Pulmonx price target raised to $16 from $15 at Wells Fargo
Feb 22
6:37am ET
Pulmonx price target raised to $17 from $16 at Citi
Feb 21
4:32pm ET
Pulmonx Announces Executive Leadership Transition and Board Changes
Feb 21
4:26pm ET
Pulmonx CEO Glen French to retire, Steve Williamson to succeed
Feb 21
4:13pm ET
Pulmonx sees FY24 revenue $81M-$84M, consensus $78.93M
Feb 21
4:12pm ET
Pulmonx reports Q4 EPS (36c), consensus (41c)
Jan 09
7:16am ET
Buy Rating for Pulmonx: Strategic Growth and Global Expansion Underpin Optimism
No recent press releases are available for LUNG
LUNG Financials
Key terms
Ad Feedback
LUNG Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LUNG Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range